Evidence map›Paper›PMID 40027190›Full record

ArticleInternational journal of medical sciences2025

Nutraceutical Evaluation of Trigonelline's Therapeutic Potential by Targeting Bladder Cancer Stem Cells and Cancer-Associated Fibroblasts via Downregulation of TGFβ3/GLI2/YAP1 Signaling Hub.

Chien-Chang Kao, Jing-Wen Shih, Huong Thi Luu Kim Huynh, Ching-Hsin Chang, Bashir Lawal, Sitthichai Iamsaard, Nur Azizah, Ritmaleni Ritmaleni, Justin Kung-Yi Lin, Po-Yang Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chien-Chang KaoDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Jing-Wen ShihPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Huong Thi Luu Kim HuynhInternational PhD Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Ching-Hsin ChangInstitute of Microbiology and Immunology, National Yang-Ming Chiao Tung University, Hsinchu 30010, Taiwan.
Bashir LawalUPMC Hillman Cancer Center, University of Pittsburgh, USA.
Sitthichai IamsaardDepartment of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Nur AzizahLaboratory of Medicinal Chemistry, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Sekip Utara,Yogyakarta, 55281, Indonesia.
Ritmaleni RitmaleniLaboratory of Medicinal Chemistry, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Sekip Utara,Yogyakarta, 55281, Indonesia.
Justin Kung-Yi LinSPs Traditional Medical Clinic, Taipei, Taiwan.
Po-Yang HuangThe Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
Alexander T H WuInternational PhD Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Ming-Che LiuSchool of Dental Technology, College of Oral Medicine, Taipei Medical University Taipei 11031, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trigonelline (TGN), an alkaloid identified in medicinal plants such as coffee (Coffea spp.) and fenugreek (Trigonella foenum-graecum), has demonstrated significant anticancer properties across various malignancies, yet its efficacy in bladder cancer (BLCA) remains underappreciated. This study investigates TGN's role in modulating cancer stem cells (CSCs) and the tumor microenvironment (TME), two key contributors to BLCA progression and chemoresistance. Through comprehensive bioinformatics analyses of BLCA patient datasets, a TGY signature (TGFβ3, GLI2, YAP1) was identified as a critical signaling hub associated with poor prognosis, therapeutic resistance, and CSC generation. Computational docking studies revealed TGN's high binding affinity to the TGY signature, TGFβ3 (ΔG = -3.9 kcal/mol), GLI2 (ΔG = -4.2 kcal/mol), YAP1 (ΔG = -3.4 kcal/mol), suggesting its potential to disrupt this signaling axis.

Indexed as

AlkaloidsUrinary Bladder NeoplasmsAdaptor Proteins, Signal TransducingAnimalsCancer-Associated FibroblastsCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMiceMolecular Docking SimulationNeoplastic Stem CellsSignal TransductionTranscription FactorsTumor MicroenvironmentAdaptor Proteins, Signal TransducingAlkaloidsTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinsbladder cancercancer-associated fibroblastscancer stem cellscisplatin resistanceTGFβ3/GLI2/YAP1 signalingtrigonelline

Identifiers

PMID40027190
PMCPMC11866525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.